Table 1

Presence of GBV-C RNA and E2 antibodies in 58 patients with fulminant hepatic failure sampled after admission to hospital and initiation of treatment. In addition, samples were obtained from 10 patients (six with GBV-C RNA and four with GBV-C E2 antibodies) on first admission to hospital before treatment. Also given is the analysis of GBV-C E2 antibodies in 43 healthy subjects

AetiologyNo of patientsNo of patients (%) with GBV-CNo of patients out of those tested with known GBV-C seroconversion after admission
RNAAntibodiesMarkersRNAAntibodies
Unknown275  (19)1-150 4  (15)8  (30)1-151 3/41/1
Viral602 (33)2 (33)——
Drug related142 (14)3 (21)5 (36)1/1—
Miscellaneous112 (18)5 (45)1-150 6 (55)1-151 0/12/3
Total589 (16)1-160 14 (24)1-150 21 (36)4/63/4
Healthy subjects43 1-164 2 (5)———

  • ↵1-150 p<0.05 compared with the healthy subjects (Fisher’s exact test).

  • ↵1-160 p<0.01 compared with the healthy subjects (Fisher’s exact test).

  • ↵1-151 One patient had both GBV-C RNA and GBV-C E2 antibodies.

  • ↵1-164 Frequency of GBV-C RNA (3 out of 100; 3%) in healthy Swedish subjects.21